Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRB191 in Extensive Stage Small Cell Lung Cancer
NCT07908667Phase 1Not yet recruiting
- Sponsor
- Novartis
- Start
- Nov 2026
- Primary completion
- Aug 2030
01
Overview
Phase 1, open-label, single-arm trial of TRB191 in small cell lung cancer (SCLC), sponsored by Novartis. Primary endpoints: Adverse Events at 24 months, Dose Limiting Toxicities at 21 days and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
TRB191
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07908667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07908667.